In this trial, 17 patients with locally advanced HNSCC received MEDI6469 prior to surgery, and the results showed that the application of OX40 agonist increased the activity of CD4+ and CD8+ T cells in blood and tumors, while its safety was confirmed (Duhen et al., 2021). This evidence concerns the gene CD8A and head and neck squamous cell carcinoma.